|
1
|
Poon IKH, Lucas CD, Rossi AG and
Ravichandran KS: Apoptotic cell clearance: Basic biology and
therapeutic potential. Nat Rev Immunol. 14:166–180. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Birge RB, Boeltz S, Kumar S, Carlson J,
Wanderley J, Calianese D, Barcinski M, Brekken RA, Huang X,
Hutchins JT, et al: Phosphatidylserine is a global
immunosuppressive signal in efferocytosis, infectious disease, and
cancer. Cell Death Differ. 23:962–978. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Green DR, Oguin TH and Martinez J: The
clearance of dying cells: Table for two. Cell Death Differ.
23:915–926. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Das A, Ganesh K, Khanna S, Sen CK and Roy
S: Engulfment of apoptotic cells by macrophages: A role of
microRNA-21 in the resolution of wound inflammation. J Immunol.
192:1120–1129. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferracini M, Rios FJ, Pecenin M and Jancar
S: Clearance of apoptotic cells by macrophages induces regulatory
phenotype and involves stimulation of CD36 and platelet-activating
factor receptor. Mediators Inflamm. 2013:9502732013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stanford JC, Young C, Hicks D, Owens P,
Williams A, Vaught DB, Morrison MM, Lim J, Williams M,
Brantley-Sieders DM, et al: Efferocytosis produces a prometastatic
landscape during postpartum mammary gland involution. J Clin
Invest. 124:4737–4752. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Murray PJ, Allen JE, Biswas SK, Fisher EA,
Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence
T, et al: Macrophage activation and polarization: Nomenclature and
experimental guidelines. Immunity. 41:14–20. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Silva MT: Secondary necrosis: The natural
outcome of the complete apoptotic program. FEBS Lett.
584:4491–4499. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fernandez-Boyanapalli RF, Falcone EL,
Zerbe CS, Marciano BE, Frasch SC, Henson PM, Holland SM and Bratton
DL: Impaired efferocytosis in human chronic granulomatous disease
is reversed by pioglitazone treatment. J Allergy Clin Immunol.
136:1399–1401.e3. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Manoussakis MN, Fragoulis GE, Vakrakou AG
and Moutsopoulos HM: Impaired clearance of early apoptotic cells
mediated by inhibitory IgG antibodies in patients with primary
Sjögren's syndrome. PLoS One. 9:e1121002014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hamon R, Homan CC, Tran HB, Mukaro VR,
Lester SE, Roscioli E, Bosco MD, Murgia CM, Ackland ML, Jersmann
HP, et al: Zinc and zinc transporters in macrophages and their
roles in efferocytosis in COPD. PLoS One. 9:e1100562014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Simpson JL, Gibson PG, Yang IA, Upham J,
James A, Reynolds PN and Hodge S: AMAZES Study Research Group:
Impaired macrophage phagocytosis in non-eosinophilic asthma. Clin
Exp Allergy. 43:29–35. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wickman G, Julian L and Olson MF: How
apoptotic cells aid in the removal of their own cold dead bodies.
Cell Death Differ. 19:735–742. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aggarwal R, Ghobrial IM and Roodman GD:
Chemokines in multiple myeloma. Exp Hematol. 34:1289–1295. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Caivano A, Laurenzana I, De Luca L, La
Rocca F, Simeon V, Trino S, D'Auria F, Traficante A, Maietti M,
Izzo T, et al: High serum levels of extracellular vesicles
expressing malignancy-related markers are released in patients with
various types of hematological neoplastic disorders. Tumor Biol.
36:9739–9752. 2015. View Article : Google Scholar
|
|
16
|
Canella A, Harshman SW, Radomska HS,
Freitas MA and Pichiorri F: The potential diagnostic power of
extracellular vesicle analysis for multiple myeloma. Expert Rev Mol
Diagn. 16:277–284. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ludwig H, Avet-Loiseau H, Bladé J,
Boccadoro M, Cavenagh J, Cavo M, Davies F, de la Rubia J, Delimpasi
S, Dimopoulos M, et al: European perspective on multiple myeloma
treatment strategies: Update following recent congresses.
Oncologist. 17:592–606. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ludwig H, Beksac M, Bladé J, Boccadoro M,
Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, et
al: Current multiple myeloma treatment strategies with novel
agents: A European perspective. Oncologist. 15:6–25. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nooka AK, Kaufman JL, Behera M, Langston
A, Waller EK, Flowers CR, Gleason C, Boise LH and Lonial S:
Bortezomib-containing induction regimens in transplant-eligible
myeloma patients: A meta-analysis of phase 3 randomized clinical
trials. Cancer. 119:4119–4128. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ribatti D, Nico B and Vacca A: Importance
of the bone marrow microenvironment in inducing the angiogenic
response in multiple myeloma. Oncogene. 25:4257–4266. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Straube C, Wehner R, Wendisch M,
Bornhäuser M, Bachmann M, Rieber EP and Schmitz M: Bortezomib
significantly impairs the immunostimulatory capacity of human
myeloid blood dendritic cells. Leukemia. 21:1464–1471. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arpinati M, Chirumbolo G, Nicolini B,
Agostinelli C and Rondelli D: Selective apoptosis of monocytes and
monocyte-derived DCs induced by bortezomib (Velcade). Bone Marrow
Transplant. 43:253–259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liang YY, Arnold T, Michlmayr A,
Rainprecht D, Perticevic B, Spittler A and Oehler R:
Serum-dependent processing of late apoptotic cells for enhanced
efferocytosis. Cell Death Dis. 5:e12642014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang YY, Rainprecht D, Eichmair E,
Messner B and Oehler R: Serum-dependent processing of late
apoptotic cells and their immunogenicity. Apoptosis. 20:1444–1456.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Arnold T, Michlmayr A, Baumann S,
Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, Bergmann M,
Bachleitner-Hofmann T and Oehler R: Plasma HMGB-1 after the initial
dose of epirubicin/docetaxel in cancer. Eur J Clin Invest.
43:286–291. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Exner R, Sachet M, Arnold T,
Zinn-Zinnenburg M, Michlmayr A, Dubsky P, Bartsch R, Steger G,
Gnant M, Bergmann M, et al: Prognostic value of HMGB1 in early
breast cancer patients under neoadjuvant chemotherapy. Cancer Med.
5:2350–2358. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bird JM, Owen RG, D'Sa S, Snowden JA,
Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, et al:
Guidelines for the diagnosis and management of multiple myeloma
2011. Br J Haematol. 154:32–75. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lamm W, Wohlfarth P, Bojic M,
Schörgenhofer C, Drach J, Gisslinger H, Worel N, Schiefer A,
Schulenburg A, Agis H, et al: Outcome in multiple myeloma patients
eligible for stem cell transplantation: A Single-center experience.
Oncology. 89:196–204. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dehle FC, Mukaro VR, Jurisevic C, Moffat
D, Ahern J, Hodge G, Jersmann H, Reynolds PN and Hodge S: Defective
lung macrophage function in lung cancer ± chronic obstructive
pulmonary disease (COPD/emphysema)-mediated by cancer cell
production of PGE2? PLoS One. 8:e615732013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McCubbrey AL and Curtis JL: Efferocytosis
and lung disease. Chest. 143:1750–1757. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Blanco B, Pérez-Simón JA, Sánchez-Abarca
LI, Carvajal-Vergara X, Mateos J, Vidriales B, López-Holgado N,
Maiso P, Alberca M, Villarón E, et al: Bortezomib induces selective
depletion of alloreactive T lymphocytes and decreases the
production of Th1 cytokines. Blood. 107:3575–3583. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Minarik J, Scudla V, Ordeltova M, Bacovsky
J, Pika T and Langova K: Prognostic significance of apoptotic index
in multiple myeloma patients treated by conventional therapy and
novel agents, thalidomide and bortezomib. Eur J Haematol.
83:528–534. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Krysko DV, Garg AD, Kaczmarek A, Krysko O,
Agostinis P and Vandenabeele P: Immunogenic cell death and DAMPs in
cancer therapy. Nat Rev Cancer. 12:860–875. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fraser DA, Laust AK, Nelson EL and Tenner
AJ: C1q differentially modulates phagocytosis and cytokine
responses during ingestion of apoptotic cells by human monocytes,
macrophages, and dendritic cells. J Immunol. 183:6175–6185. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yadav A, Saini V and Arora S: MCP-1:
Chemoattractant with a role beyond immunity: A review. Clin Chim
Acta. 411:1570–1579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Roca H, Varcos ZS, Sud S, Craig MJ and
Pienta KJ: CCL2 and interleukin-6 promote survival of human CD11b+
peripheral blood mononuclear cells and induce M2-type macrophage
polarization. J Biol Chem. 284:34342–34354. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kobayashi M, Jeschke MG, Shigematsu K,
Asai A, Yoshida S, Herndon DN and Suzuki F: M2b monocytes
predominated in peripheral blood of severely burned patients. J
Immunol. 185:7174–7179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lens SM, Tesselaar K, van Oers MH and van
Lier RA: Control of lymphocyte function through CD27-CD70
interactions. Semin Immunol. 10:491–499. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Moon H, Na HY, Chong KH and Kim TJ: P2X7
receptor-dependent ATP-induced shedding of CD27 in mouse
lymphocytes. Immunol Lett. 102:98–105. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tagoug I, Plesa A and Dumontet C:
Bortezomib influences the expression of malignant plasma cells
membrane antigens. Eur J Pharmacol. 706:11–16. 2013. View Article : Google Scholar : PubMed/NCBI
|
